Solution details Clause Samples

The 'Solution Details' clause defines the specific features, components, and functionalities of the product or service being provided under the agreement. It typically outlines the technical specifications, performance requirements, and any deliverables that the solution must meet, often referencing supporting documents or schedules for further detail. By clearly describing what is to be delivered, this clause ensures both parties have a mutual understanding of expectations, reducing the risk of disputes over scope or quality.
Solution details. [Guidance: please describe the method of working that is proposed. This should be provided principally in terms of the DWP information, systems or services involved, and how they are handled, stored, viewed, protected, etc. The aspect of DWP information, systems or services storage should consider permanent storage (such as a designated long-term repository), temporary storage (such as working on a checked out file before checking it back in), and transient storage (such as short term residence in communication devices)...]
View SourceView Similar (7)
Solution details. Customer Information TELUS Representative
View SourceView Similar (2)
Solution details. New Operating Model
View Source

Related to Solution details

  • Notice Details Party A: Swiss Re Financial Products Corporation Address: ▇▇ ▇▇▇▇ ▇▇/▇▇/ ▇▇▇▇▇▇ ▇▇/▇▇/ ▇▇▇▇▇ ▇▇▇ ▇▇▇▇ ▇▇ ▇▇▇▇▇ ▇▇▇ Facsimile No.: +▇ ▇▇▇ ▇▇▇ ▇▇▇▇ Attention: Head of Operations Party B: Permanent Financing (No. 6) PLC 27 Address: ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇ Facsimile Number: 020 7566 0975 Attention: The Secretary With a copy to: (i) the Security Trustee:

  • Technical Support Services 2.1 The technical support services (the "Services"): Party A agrees to provide to Party B the relevant services requested by Party B, which are specified in Exhibit 1 attached hereto ("Exhibit 1").

  • Product Support Not applicable

  • Invoice Detail All charges for services rendered or for reimbursement of expenses authorized by Department pursuant to the Grant Work Plan shall be submitted to Department in sufficient detail for a proper pre-audit and post-audit to be performed. The Grantee shall only invoice Department for deliverables that are completed in accordance with the Grant Work Plan.

  • Tests and Preclinical and Clinical Trials The preclinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, and are intended to be or have been submitted to FDA or other comparable governmental entities, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, applicable Authorizations, and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and, for studies submitted to regulatory authorities for approval, in all material respects, current Good Clinical Practices and Good Laboratory Practices and any applicable rules and regulations of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies and trials contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus are, to the Company’s knowledge, accurate and complete and fairly present the data derived from such studies and trials in all material respects; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies or trials, the results of which the Company believes materially call into question the study or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or correspondence from the FDA or any governmental entity requiring the termination or suspension of any preclinical studies or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.